Global Covid-19 Vaccination Roll-out causes delay to RhoVac’s Phase IIb study
RhoVac AB ("RhoVac"), a Swedish cancer immunotherapy company, announces today, March 8[th] , 2021, that its clinical phase IIb study, “BRaVac”, in prostate cancer, will be somewhat further delayed as Covid-19 vaccinations are rolled out to the study population.As Covid-19 vaccinations are presently being rolled out in the age brackets of our study, some patients will have their RV001 treatment initiation deferred until after vaccination. The delay caused by these deferrals is difficult to estimate presently. However, the previous target of having full recruitment by Q2 no longer seems